Zenas BioPharma, Inc. (NASDAQ:ZBIO) Stock Has Consensus Target Price of $46.71 According to Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $46.71.

Several equities research analysts have recently issued reports on ZBIO shares. Weiss Ratings cut Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, October 28th. Guggenheim restated a “buy” rating and set a $55.00 price objective on shares of Zenas BioPharma in a report on Wednesday, September 30th. HC Wainwright reiterated a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a research report on Tuesday, October 13th. Finally, Morgan Stanley initiated coverage on shares of Zenas BioPharma in a research note on Tuesday, October 20th. They set an “equal weight” rating and a $32.00 target price for the company.

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $28.26 on Friday. The firm has a market capitalization of $1.84 billion, a PE ratio of -3.00 and a beta of -0.88. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. The company has a 50 day moving average price of $28.98 and a 200-day moving average price of $25.14. Zenas BioPharma has a 52 week low of $13.50 and a 52 week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.24) by ($0.41). The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.00 million. As a group, equities research analysts expect that Zenas BioPharma will post -5.94 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. raised its stake in Zenas BioPharma by 3.6% in the third quarter. Russell Investments Group Ltd. now owns 13,193 shares of the company’s stock valued at $356,000 after buying an additional 453 shares during the last quarter. Candriam S.C.A. acquired a new stake in Zenas BioPharma in the third quarter worth about $17,725,000. Alps Advisors Inc. grew its stake in shares of Zenas BioPharma by 35.6% during the third quarter. Alps Advisors Inc. now owns 86,369 shares of the company’s stock worth $2,329,000 after acquiring an additional 22,694 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zenas BioPharma during the third quarter worth about $90,000. Finally, Sterling Capital Management LLC increased its holdings in shares of Zenas BioPharma by 1,090.0% during the third quarter. Sterling Capital Management LLC now owns 1,190 shares of the company’s stock valued at $32,000 after acquiring an additional 1,090 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune diseases and other serious immune-mediated conditions. The company’s research is centered on treatments designed to modulate B-cell activity and restore balance to the immune system.

Zenas’ lead product candidate is obexelimab, an investigational bifunctional antibody designed to bind CD19 on B cells and Fc gamma receptor IIb. By engaging both targets, obexelimab is intended to inhibit pathogenic B-cell activity without broadly depleting B cells.